Roche Dives Into Obesity Drug Market via Carmot Merger Deal

Roche Roche Holding AG, a Switzerland-based pharma company, announced on Monday, Dec. 4, that it acquired Carmot Therapeutics for $2.7 billion. The companies entered into a definitive agreement for the buyout deal.

The transaction also includes three of Carmot Therapeutics's promising assets in obesity and diabetes but are still in the clinical stage. These drugs are said to have best-in-class potential in treating the said diseases. According to Reuters, aside from the upfront purchase price, Roche confirmed that equity holders of Carmot will also get payments of up to $400 million if milestones are achieved.

New Drug Portfolio that Roche Will Gain from the Deal

The staff of Carmot is expected to move to Roche's pharmaceuticals division once the deal is completed, which can happen within the first quarter of 2024. The acquisition will give Roche access to the obesity drug producer's current R&D portfolio, which means all its clinical and pre-clinical assets are included.

The three major assets in the Carmot portfolio that Roche will have access to are CT-388, an obesity treatment currently in Phase 2; CT-996 (Phase 1), a type of oral drug for obesity and diabetes patients; and CT-868, a Phase 2 injectable drug for treating the mentioned medical conditions.

Upon the Finalization of the Deal

Roche said that once the deal is closed, it will have exclusive access to Carmot's advanced Chemotype Evolution discovery program focused on metabolism. This will help the company in augmenting its research and development efforts and portfolio in metabolic and cardiovascular diseases.

"Obesity is a heterogeneous disease, which contributes to many other diseases that together comprise a significant health burden worldwide," Roche Group's chief executive officer, Thomas Schinecker, said in a press release. "By combining Carmot's portfolio with programs in our Pharmaceuticals pipeline and our Diagnostics expertise and portfolio of products across cardiovascular and metabolic diseases, we are aiming to improve the standard of care and positively impact patients' lives."

Roche's chief medical officer and head of global product development, Levi Garraway, also commented, "We are encouraged by the clinical data for the lead asset CT-388, which demonstrated substantial weight loss in Phase 1b. These data suggest the potential for a differentiated profile to treat obesity and its associated diseases and the broad Carmot portfolio offers different routes of administration and opportunities to develop combination therapies that treat obesity and potentially other indications."

Photo by: Roche Media Library